Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This technical report provides a comprehensive guidance framework for implementing the Sterile Insect Technique (SIT) as a vector control tool against Aedes-borne diseases. Published by the World Health Organization and the International Atomic Energy Agency, the document outlines essential components for decision-making, testing, and implementing SIT programs. It includes detailed methodologies for health and environmental risk assessments associated with Aedes mosquitoes. The report aims to aid public health professionals, researchers, and decision-makers in the effective application of SIT to combat diseases such as dengue and Zika. It emphasizes collaboration and consultation across various scientific disciplines.

Vector control. --- Dengue viruses.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Dengue is the most important mosquito-transmitted viral disease in humans. Half of the world population is at risk of infection, mostly in tropical and sub-tropical areas. The World Health Organization (WHO) estimates that 50 to 100 million infections occur yearly, with 50,000 to 100,000 deaths related to dengue, mainly in children. Recent estimates show higher numbers, up to three times more, with 390 million estimated dengue infections per year, among which 96 million apparent infections (Bhatt et al. 2013). Initially localized to South-East Asia, dengue virus (DENV) started its spread in Latin America in the 80s. Little is known about DENV spread in Africa, but multiple seroprevalence surveys over several years are now clearly showing endemic areas in East and West Africa (Brady et al. 2013). Finally, due to global warming and intense traveling there is a risk of global spread towards more temperate regions, and both US Key islands (FL) and southern Europe recently faced DENV outbreaks. There are currently no specific treatments or vaccines available. Even though several dengue vaccines are in the pipeline, clear correlates of protection are still lacking. The recent failure of the live-attenuated Sanofi vaccine Phase 2b trial (Sabchareon et al. 2013) and the lack of correlation between clinical protection and in vitro neutralization assays, clearly underlines the necessity to better understand the role of the different components of the immune system in protection against dengue virus infection and the requirement for the development of additional and/or improved predictive assays. The aim of this research topic is to provide novel data, opinions and literature reviews on the best immune correlates of protection and recent advances in the immune response to DENV infection that can allow rapid progress of dengue vaccines. Authors can choose to submit original research papers, reviews or opinions on pre-clinical or clinical observations that will help unify the field, with perspectives from epidemiology, virology, immunology and vaccine developers. This research topic will discuss different aspects of the protective immune response to DENV that can influence vaccine development. It will include a review of epidemiological data generated in the field, which will address spatio-temporal diversity of DENV epidemics, the importance of cross-reactive protection and of the time-interval between infections as a predictor of disease. It will further include a review of the role of both the innate and adaptive immunity in DENV infection control, and discuss the usefulness of new improved animal models in dissecting the role of each immunological compartment, which will help define new correlate of immune protection. New data concerning the DENV structure and anti-dengue antibody structure will address the necessity of improved neutralization assays. The ultimate test to prove vaccine efficacy and study immune correlates of protection in humans before large trials will open up the discussion on human DENV challenges using controlled attenuated viral strains. Finally, the role of vaccines, administered in flavi-immune populations, in the modification of future epidemics will also be approached and will include novel studies on mosquitoes infection thresholds.

Dengue viruses. --- Vaccines. --- Monocytes --- NK cells --- Dendritic Cells --- Dengue --- Antibodies --- protection --- Vaccines --- T cells --- Macrophages --- Immunity

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Dengue is the most important mosquito-transmitted viral disease in humans. Half of the world population is at risk of infection, mostly in tropical and sub-tropical areas. The World Health Organization (WHO) estimates that 50 to 100 million infections occur yearly, with 50,000 to 100,000 deaths related to dengue, mainly in children. Recent estimates show higher numbers, up to three times more, with 390 million estimated dengue infections per year, among which 96 million apparent infections (Bhatt et al. 2013). Initially localized to South-East Asia, dengue virus (DENV) started its spread in Latin America in the 80s. Little is known about DENV spread in Africa, but multiple seroprevalence surveys over several years are now clearly showing endemic areas in East and West Africa (Brady et al. 2013). Finally, due to global warming and intense traveling there is a risk of global spread towards more temperate regions, and both US Key islands (FL) and southern Europe recently faced DENV outbreaks. There are currently no specific treatments or vaccines available. Even though several dengue vaccines are in the pipeline, clear correlates of protection are still lacking. The recent failure of the live-attenuated Sanofi vaccine Phase 2b trial (Sabchareon et al. 2013) and the lack of correlation between clinical protection and in vitro neutralization assays, clearly underlines the necessity to better understand the role of the different components of the immune system in protection against dengue virus infection and the requirement for the development of additional and/or improved predictive assays. The aim of this research topic is to provide novel data, opinions and literature reviews on the best immune correlates of protection and recent advances in the immune response to DENV infection that can allow rapid progress of dengue vaccines. Authors can choose to submit original research papers, reviews or opinions on pre-clinical or clinical observations that will help unify the field, with perspectives from epidemiology, virology, immunology and vaccine developers. This research topic will discuss different aspects of the protective immune response to DENV that can influence vaccine development. It will include a review of epidemiological data generated in the field, which will address spatio-temporal diversity of DENV epidemics, the importance of cross-reactive protection and of the time-interval between infections as a predictor of disease. It will further include a review of the role of both the innate and adaptive immunity in DENV infection control, and discuss the usefulness of new improved animal models in dissecting the role of each immunological compartment, which will help define new correlate of immune protection. New data concerning the DENV structure and anti-dengue antibody structure will address the necessity of improved neutralization assays. The ultimate test to prove vaccine efficacy and study immune correlates of protection in humans before large trials will open up the discussion on human DENV challenges using controlled attenuated viral strains. Finally, the role of vaccines, administered in flavi-immune populations, in the modification of future epidemics will also be approached and will include novel studies on mosquitoes infection thresholds.

Dengue viruses. --- Vaccines. --- Monocytes --- NK cells --- Dendritic Cells --- Dengue --- Antibodies --- protection --- Vaccines --- T cells --- Macrophages --- Immunity --- Monocytes --- NK cells --- Dendritic Cells --- Dengue --- Antibodies --- protection --- Vaccines --- T cells --- Macrophages --- Immunity

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Dengue --- Dengue Virus. --- Dengue. --- 616.91 --- Break-Bone Fever --- Breakbone Fever --- Classical Dengue --- Classical Dengue Fever --- Dengue Fever --- Break Bone Fever --- Classical Dengue Fevers --- Classical Dengues --- Dengue Fever, Classical --- Dengue, Classical --- Fever, Break-Bone --- Fever, Breakbone --- Fever, Dengue --- Breakbone Fever Virus --- Breakbone Fever Viruses --- Dengue Viruses --- Fever Virus, Breakbone --- Fever Viruses, Breakbone --- Virus, Breakbone Fever --- Virus, Dengue --- Viruses, Breakbone Fever --- Viruses, Dengue --- Acute infectious febrile diseases --- Dengue virus --- 616.91 Acute infectious febrile diseases --- Dengue virus. --- Dengue. Therapie. --- Dengue. Diagnostiek. --- Dengue. Virus. --- Dengue. Traitement. --- Dengue. Diagnostic. --- Dengue Virus

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Zika virus (ZIKV) is a mosquito-borne member of the Flaviviridae family that historically has been associated with mild febrile illness. However, the recent outbreaks in Brazil in 2015 and its rapid spread throughout South and Central America and the Caribbean, together with its association with severe neurological disorders—including fetal microcephaly and Guillain-Barré syndrome in adults—have changed the historic perspective of ZIKV. Currently, ZIKV is considered an important public health concern that has the potential to affect millions of people worldwide. The significance of ZIKV in human health and the lack of approved vaccines and/or antiviral drugs to combat ZIKV infection have triggered a global effort to develop effective countermeasures to prevent and/or treat ZIKV infection. In this Special Issue of Viruses, we have assembled a collection of 32 research and review articles that cover the more recent advances on ZIKV molecular biology, replication and transmission, virus–host interactions, pathogenesis, epidemiology, vaccine development, antivirals, and viral diagnosis.

microRNAs --- antivirals --- reverse genetics --- nucleic acid computation --- viral pathogenesis --- plaque reduction neutralization test --- clinical trials --- viral genetic variation --- viral fitness --- pregnancy --- type I IFN antagonist --- prM-E proteins --- eye --- replicon --- antiviral responses --- Bacterial artificial chromosome --- gene expression --- NS1 protein --- viral permissiveness --- ZIKV–host interactions --- reporter virus --- viral persistence --- blood-retinal barrier --- virus like particles --- emerging arbovirus --- Non-human primates --- heme-oxygenase 1 --- mosquito surveillance --- antiviral compounds --- ZIKV-associated neurologic disorders --- external quality assessment --- outbreak control --- therapeutics --- cryptic promoter silencing --- testis --- neurons --- mutagenesis --- RNA-seq --- microsphere immunoassay --- host-directed antivirals --- molecular diagnostics --- Bayesian analyses --- astrocytomas --- Full-length cDNA infectious clones --- viral pathogenicity --- neural progenitor cells --- full-length molecular clone --- antiviral --- multiplex nucleic acid detection --- Asian-lineage --- nucleic acid strand exchange --- IgA --- African-lineage --- vaccines --- Zika --- research models and tools --- immune response --- IgG avidity tests --- polymerase chain reaction --- Asian lineage --- sexual transmission --- TLR7/8 --- neuropathogenesis --- cross-reactions --- genetic variability --- mosquito --- ZIKV --- infectious cDNA --- prostate --- host genetic variation --- monoclonal antibodies --- optimised --- anti-viral immunity --- QCMD --- arbovirus --- FSS13025 --- MR766 --- NS5 --- EQA --- testicular cells --- virus attachment --- flavivirus --- mosquito-borne flavivirus --- dsRNA --- boolean logic-processing nucleic acid probes --- Ziks virus --- viral replication --- Aedes aegypti --- infection --- natural history --- infectious RNA --- zika virus --- chimeric viruses --- subgenomic replicon --- replication --- human brain glial cells --- microglia cells --- hepatocytes --- bacterial artificial chromosome --- detoxification and immune system responses --- testes --- dengue viruses --- Zika virus --- insecticide resistance --- NS2A protein --- plasmid toxicity --- cell surface receptors --- serology --- viral evolution --- laboratory preparedness --- flaviviruses --- Tet-inducible --- dengue virus --- diagnosis --- assay standardization --- infectious clone --- ELISA --- innate response --- congenital Zika syndrome --- secondary infections --- apoptosis --- viral survival --- ocular --- validated --- rhesus macaques --- neuroinflammation --- placenta cells --- NHP --- Zika virus (ZIKV) --- point-of-care diagnostics --- isothermal nucleic acid amplification --- microcephaly --- cytopathic effects --- indirect immunofluorescence --- fetal infection --- therapy --- siRNA --- viral counteraction --- neural cells --- silvestrol --- eIF4A --- microRNAs --- antivirals --- reverse genetics --- nucleic acid computation --- viral pathogenesis --- plaque reduction neutralization test --- clinical trials --- viral genetic variation --- viral fitness --- pregnancy --- type I IFN antagonist --- prM-E proteins --- eye --- replicon --- antiviral responses --- Bacterial artificial chromosome --- gene expression --- NS1 protein --- viral permissiveness --- ZIKV–host interactions --- reporter virus --- viral persistence --- blood-retinal barrier --- virus like particles --- emerging arbovirus --- Non-human primates --- heme-oxygenase 1 --- mosquito surveillance --- antiviral compounds --- ZIKV-associated neurologic disorders --- external quality assessment --- outbreak control --- therapeutics --- cryptic promoter silencing --- testis --- neurons --- mutagenesis --- RNA-seq --- microsphere immunoassay --- host-directed antivirals --- molecular diagnostics --- Bayesian analyses --- astrocytomas --- Full-length cDNA infectious clones --- viral pathogenicity --- neural progenitor cells --- full-length molecular clone --- antiviral --- multiplex nucleic acid detection --- Asian-lineage --- nucleic acid strand exchange --- IgA --- African-lineage --- vaccines --- Zika --- research models and tools --- immune response --- IgG avidity tests --- polymerase chain reaction --- Asian lineage --- sexual transmission --- TLR7/8 --- neuropathogenesis --- cross-reactions --- genetic variability --- mosquito --- ZIKV --- infectious cDNA --- prostate --- host genetic variation --- monoclonal antibodies --- optimised --- anti-viral immunity --- QCMD --- arbovirus --- FSS13025 --- MR766 --- NS5 --- EQA --- testicular cells --- virus attachment --- flavivirus --- mosquito-borne flavivirus --- dsRNA --- boolean logic-processing nucleic acid probes --- Ziks virus --- viral replication --- Aedes aegypti --- infection --- natural history --- infectious RNA --- zika virus --- chimeric viruses --- subgenomic replicon --- replication --- human brain glial cells --- microglia cells --- hepatocytes --- bacterial artificial chromosome --- detoxification and immune system responses --- testes --- dengue viruses --- Zika virus --- insecticide resistance --- NS2A protein --- plasmid toxicity --- cell surface receptors --- serology --- viral evolution --- laboratory preparedness --- flaviviruses --- Tet-inducible --- dengue virus --- diagnosis --- assay standardization --- infectious clone --- ELISA --- innate response --- congenital Zika syndrome --- secondary infections --- apoptosis --- viral survival --- ocular --- validated --- rhesus macaques --- neuroinflammation --- placenta cells --- NHP --- Zika virus (ZIKV) --- point-of-care diagnostics --- isothermal nucleic acid amplification --- microcephaly --- cytopathic effects --- indirect immunofluorescence --- fetal infection --- therapy --- siRNA --- viral counteraction --- neural cells --- silvestrol --- eIF4A